A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery
Open accessPublished version of a preprint
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Abstract Current RNA vaccines against SARS-CoV-2 are limited by instability of both the RNA and the lipid nanoparticle delivery system, requiring storage at −20°C or −70°C and compromising universally accessible vaccine distribution. This study demonstrates the thermostability and adaptability of a nanostructured lipid carrier (NLC) RNA vaccine delivery system for use in pandemic preparedness and pandemic response. Liquid NLC is stable at refrigerated temperatures for ≥ 1 year, enabling stockpiling and rapid deployment by point-of-care mixing with any vaccine RNA. Alternatively, NLC complexed with RNA may be readily lyophilized and stored at room temperature for ≥ 8 months or refrigerated temperature for ≥ 21 months. This thermostable RNA vaccine platform could significantly improve distribution of current and future pandemic response vaccines, particularly in low-resource settings. One Sentence Summary An RNA vaccine delivery system stable at room temperature for 8+ months and refrigerated for 21+ months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“The Emergency Use Authorization granted to two safe and highly effective mRNA vaccines targeting SARS-CoV-2, less than 1 year after sequencing the novel coronavirus, highlights the power of this new technology.(5,6) However, one of the biggest challenges facing these extraordinary new vaccines is the ability to succes…”
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 1×
“RNA vaccines can be rapidly adapted to new targets and manufactured using sequence-independent operations, thus reducing the cost and time to develop new vaccines, particularly in pandemic settings.(4) The Emergency Use Authorization granted to two safe and highly effective mRNA vaccines targeting SARS-CoV-2, less tha…”
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · cited 1×
“Engineering of the RNA has previously been done in order to stabilize it, as reviewed by Sahin and colleagues, 12 but stability problems remain.”
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127 · cited 2×
“Thus, RNA delivery formulations are needed to stabilize and protect RNA molecules from degradation (reviewed by Kowalski et al.(14) and Guan et al.”
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927 · cited 1×
“This results in 70– 100 nm diameter RNA/LNP complexes that protect the RNA from RNase degradation and allow successful endocytosis by the cell.(18,20) However, stability of both the RNA and LNP remain an issue, with sensitivity to frozen temperatures resulting in detrimental impacts to their colloidal stability after…”
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 694
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Research works printed but not linked: 13
- Deering, 2014, Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines, Expert Opin. Drug Deliv., 11, 885, 10.1517/17425247.2014.901308 · DOI · Paper page
- Zhang, 2019, Advances in mRNA vaccines for infectious diseases, Front Immunol., 10, 594, 10.3389/fimmu.2019.00594 · DOI · Paper page
- Kumru, 2014, Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies, Biologicals, 42, 237, 10.1016/j.biologicals.2014.05.007 · DOI · Paper page
- Chen, 2013, Desirable attributes of vaccines for deployment in low-resource settings, J. Pharm. Sci., 102, 29, 10.1002/jps.23352 · DOI
- Zhao, 2014, Lipid nanoparticles for gene delivery, Adv. Genet., 88, 13, 10.1016/B978-0-12-800148-6.00002-X · DOI · Paper page
- Fonte, 2016, Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery, J. Control Release, 225, 75, 10.1016/j.jconrel.2016.01.034 · DOI · Paper page
- Alberer, 2017, Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial, Lancet, 390, 1511, 10.1016/S0140-6736(17)31665-3 · DOI · Paper page
- Franze, 2018, Lyophilization of liposomal formulations: still necessary, still challenging, Pharmaceutics, 10, 139, 10.3390/pharmaceutics10030139 · DOI · Paper page
- Wang, 2019, Lyophilized liposome-based parenteral drug development: reviewing complex product design strategies and current regulatory environments, Adv. Drug Deliv. Rev., 151-152, 56, 10.1016/j.addr.2019.03.003 · DOI
- Leung, 2012, Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core, J. Phys. Chem. C Nanomater. Inter., 116, 18440, 10.1021/jp303267y · DOI · Paper page
- Chen, 2010, An overview of liposome lyophilization and its future potential, J. Control Release, 142, 299, 10.1016/j.jconrel.2009.10.024 · DOI · Paper page
- Kramer, 2018, Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach, Int. J. Nanomedicine, 13, 3689, 10.2147/IJN.S159839 · DOI
- Alameh, 2021, Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses, Immunity, 54, 2877, 10.1016/j.immuni.2021.11.001 · DOI · Paper page
Cited by
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
Voigt, E. A., Gerhardt, A., Hanson, D., Jennewein, M. F., Battisti, P., Reed, S., Singh, J., Mohamath, R., Bakken, J., Beaver, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00549-y · Cited by 89
Self-citationRise of the RNA machines – self-amplification in mRNA vaccine design
Comes, J. D. G., Pijlman, G. P., & Hick, T. A. H. (2023) · Trends in Biotechnology · doi:10.1016/j.tibtech.2023.05.007 · Cited by 87
Self-Amplifying RNA Approach for Protein Replacement Therapy
Papukashvili, D., Rcheulishvili, N., Liu, C., Ji, Y., He, Y., & Wang, P. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112884 · Cited by 76
Metadata
- Authors
- Gerhardt, A., Voigt, E., Archer, M., Reed, S., Larson, E., Van Hoeven, N., Kramer, R., Fox, C., & Casper, C.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 25
- Pages
- 205-214
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W4220709413
- Cited by
- 89
- References
- 29
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery. https://app.cochat.ai/papers/10.1016/j.omtm.2022.03.009
- The paper
- Gerhardt, A., Voigt, E., Archer, M., Reed, S., Larson, E., Van Hoeven, N., Kramer, R., Fox, C., & Casper, C. (2022). A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2022.03.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.